Premium
Role of β 3 ‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis
Author(s) -
Trebicka Jonel,
Hennenberg Martin,
Schulze Pröbsting Andrea,
Laleman Wim,
Klein Sabine,
Granzow Michaela,
Nevens Frederik,
Zaagsma Johan,
Heller Jörg,
Sauerbruch Tilman
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23222
Subject(s) - portal hypertension , medicine , endocrinology , cirrhosis , hyperdynamic circulation , portal venous pressure , hepatic stellate cell , cyclic guanosine monophosphate , vascular resistance , nitric oxide , blood pressure
Increased intrahepatic resistance and splanchnic blood flow cause portal hypertension in liver cirrhosis. Nonselective β‐adrenoceptor (β‐AR) antagonists have beneficial effects on hyperdynamic circulation and are in clinical use. In this context, the role of the β 3 ‐AR is undefined. Here we investigated their expression and role in portal hypertension in patients and rats with liver cirrhosis. We analyzed cirrhotic human and rat tissues (liver, splanchnic vessels) and primary rat cells. Protein expression of β 3 ‐AR was determined by western blot and messenger RNA (mRNA) levels by reverse‐transcription polymerase chain reaction (RT‐PCR). Activities of Rho‐kinase and the nitric oxide (NO) effector protein kinase G (PKG) were assessed by way of substrate phosphorylation (moesin, vasodilator‐stimulated phosphoprotein [VASP]). Cyclic 3′,5′ adenosine monophosphate (cAMP) accumulation was determined by an enzyme‐immunoassay kit. The effects of selective β 3 ‐AR agonists (CGP12177A, BRL37344) and antagonist (SR59230A) were investigated by collagen matrix contraction of hepatic stellate cells (HSCs), in situ liver perfusions, and in vivo hemodynamic parameters in bile duct ligation and carbon tetrachloride intoxication in cirrhotic rats. In cirrhosis of humans and rats, β 3 ‐AR expression is markedly increased in hepatic and in splanchnic tissues. Stimulation of β 3 ‐AR leads to relaxation of HSCs by way of cAMP accumulation, and by inhibition of Rho‐kinase activity; any role of NO and its effector PKG was not observed. β 3 ‐AR agonists decrease intrahepatic resistance and portal pressure in cirrhotic rats. Conclusion: There is a marked hepatic and mesenteric up‐regulation of β 3 ‐ARs in human cirrhosis and in two different animal models of cirrhosis. The β 3 ‐AR‐agonists should be further evaluated for therapy of portal hypertension. (H EPATOLOGY 2009.)